Mum diagnosed with breast cancer months after daughter treated for skin cancer
A Scottish mum was diagnosed with breast cancer just 16 months after her daughter was diagnosed with melanoma.
Michelle Harris, a teacher of complex needs, recalls her shock when she was diagnosed with skin cancer in November 2019.
The 38-year-old, who is now in remission, was on a family holiday to Finland when her husband Alistair first noticed a mole on her back had changed shape and was growing larger.
The mum-of-two had noticed the mole had also become itchy, so she visited her GP and was referred to University Hospital Monklands in Airdrie for tests, which confirmed she had cancer. Cancer Research UK Family holiday with Michelle Harris front right and her mum Lorraine Taylor.
Recalling the tough moment of telling her children, Abby, 17, and Kaden, 13, about her diagnosis, Michelle said: 'I was very matter of fact and open when I told the children I had cancer.
'I explained that doctors had told me it was stage 2b melanoma, so they had gotten the cancer early. Although I had to go through an operation, I was going to be okay.
She added: 'I just had to get on with things. It was good that the NHS were there to look after me so well, and my GP was fantastic.' Cancer Research UK Left to right, Michelle Harris and her mum, Lorraine Taylor, set off on holiday.
Michelle had surgery on November 30, 2019, to remove the mole as well as lymph nodes from under her arms.
She required no further treatment but has regular check-ups on other areas of her body where there are moles.
Just 16 months after her diagnosis, her mum, who had helped her through treatment, was told that she had breast cancer.
Lorraine Taylor had no symptoms when she attended a routine breast screening appointment.
However, a few weeks after the screening, the 64-year-old was asked to attend the West Scotland Breast Screening Centre in Glasgow, and in March 2021, she was given the news. Cancer Research UK Left to right, Michelle Harris, 38, and her daughter Abby Harris, 17, getting ready to go on holiday.
'I went to the appointment on my own, which, looking back on it, I think was a mistake,' Lorraine said.
'I remember coming out of the appointment and feeling shell-shocked as I called my daughter Michelle to give her the news.'
Lorrain said, although it was a 'really stressful' time, she felt lucky the screening had caught the cancer early.
'Michelle was a great support to me, and so was my husband Martin, who came with me to appointments after that,' she said.
She eventually had the surgery at Kings Park Hospital in June 2022, followed by eight sessions of radiotherapy at the Lanarkshire Beatson in Airdrie.
She was prescribed the hormone therapy drug Tamoxifen and receives annual mammograms.
Lorraine will join her daughter, Michelle, and her granddaughter, Abby, on the start line of Cancer Research UK's Race for Life at Glasgow Green on May 18.
Speaking on the race, Michelle said it was 'personal' for her and her mum.
'Cancer turns lives upside down, steals precious moments and affects far too many of us,' she said.
'We talk almost every day and plan weekends away together. Mum was an amazing support for me when I was diagnosed, and when mum faced cancer, I was right there for her.
'Taking part in Race for Life is not just about the miles. It's about giving back to a cause that has given our family and so many others hope.
'Research means more people are getting through cancer. We're proud to support that, to cross the finish line in honour of those going through cancer right now and also in memory of some friends and colleagues we have sadly lost to cancer.'
Abby, 17, spoke about her participation, saying: 'My mum and my gran are both amazing, strong women and I'll be proud to be by their side at Race for Life Glasgow.'
Lisa Adams, Cancer Research UK's spokeswoman in Scotland, said: 'We are grateful to Michelle, Lorraine and Abby for their support and know their family story will make an impact on everyone who hears it.
'Sadly, nearly 1 in 2 of us will get cancer in our lifetime, but all of us can support the research that will beat it. We're proud that Race for Life has had such a positive impact. Every pound raised supports our life-saving work, which has helped double cancer survival in the UK over the last 50 years.
'We'd love for as many people as possible across Scotland and beyond to join us at Race for Life. There is an event for everyone and we mean everyone. Our events are strictly non-competitive which means everyone can have a go- and love every minute. There's no pressure to finish in a certain time, just give it what you can. Lace up and join in.
'Whether people are living with cancer, taking part in honour of or in memory of a loved one with cancer, in it for the medals or just for the fun of fundraising, there is a place for everyone.'
Get all the latest news from around the country Follow STV News
Scan the QR code on your mobile device for all the latest news from around the country
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Argus
43 minutes ago
- South Wales Argus
Dentists slam Welsh Government's NHS dental reforms
The British Dental Association Cymru has warned the Welsh Government that the changes could lead to an exodus from the workforce and should be paused for further trials. The proposed reforms aim to improve oral health, increase prevention, and provide better value for money. However, a survey indicates that only two per cent of dentists believe the changes will support NHS dentistry's sustainability. Just five per cent agree the reforms will enhance prevention, and eight per cent think they will improve access to NHS care. A significant concern is the shift in patient appointments to up to 24 months apart, which could limit early disease detection, including oral cancers. The changes also propose moving patients to a centralised database, potentially fragmenting family care. The reforms are expected to be introduced next year.
North Wales Chronicle
an hour ago
- North Wales Chronicle
Women with genetic cancer risk being ‘missed' due to testing gaps
A lack of testing for Lynch syndrome also means some cancer patients are unaware of their risk of developing other cancers, academics said. Lynch syndrome is a rare condition which runs in families which puts people at a higher risk of developing cancers of the bowel, womb and ovaries. It is caused by a mutation in the gene that fixes mistakes in DNA when it is copied, which can lead to uncontrolled cell growth. Patients with bowel or womb cancer should have their tumours assessed for markers of Lynch syndrome, according to guidance for the NHS. If these markers are identified, patients should be referred for genetic testing so the diagnosis can be confirmed and they can get support and advice about cancer risk for themselves and their family. A new study by academics at the University of Edinburgh found not all womb cancer patients are being sent for genetic testing. Researchers examined data on 2,500 womb cancer patients across the UK and Ireland between 2022 and 2023. We have launched a Guide to #LynchSyndrome to help provide information and support to anyone who thinks they may have it, that it may run in the family, or have found out they have — The Eve Appeal (@eveappeal) February 13, 2023 They found that 91% of tumours were tested for markers of Lynch syndrome, but the test results were not routinely communicated to the wider clinical team. This means that follow-up genetic counselling and blood tests were not always arranged. Of the 181 participants eligible for genetic counselling, just under two-thirds (64%) were referred for appointments, according to the study, which has been published in the journal BMJ Oncology. Researchers said those who were referred faced long waits, resulting in high dropout rates, meaning only 48% of those eligible went on to get the test. Today's #LynchSyndromeAwarenessDay. Our policy team sat down with our supporter, Jane, to share her experience. As well as highlighting what else needs to be done to improve Lynch syndrome care. Read our blog: — Bowel Cancer UK (@bowelcanceruk) March 22, 2025 Experts from the university said gaps in testing mean some womb cancer patients with Lynch syndrome go undetected. Family members are also left vulnerable to cancer risk, unaware they may have the condition. Dr Neil Ryan, from the University of Edinburgh, who leads the UK audit and research collaborative in obstetrics and gynaecology, said: 'Despite clear guidance and excellent rates of tumour testing, too many women with Lynch syndrome are still being missed because they're not referred for definitive blood testing in a timely way. 'This not only denies them the chance to reduce their future cancer risk but also prevents their relatives from being tested and protected. 'Tumour testing is only cost-effective if it leads to diagnosis — we urgently need to make mainstream testing truly mainstream.'
Rhyl Journal
2 hours ago
- Rhyl Journal
Women with genetic cancer risk being ‘missed' due to testing gaps
A lack of testing for Lynch syndrome also means some cancer patients are unaware of their risk of developing other cancers, academics said. Lynch syndrome is a rare condition which runs in families which puts people at a higher risk of developing cancers of the bowel, womb and ovaries. It is caused by a mutation in the gene that fixes mistakes in DNA when it is copied, which can lead to uncontrolled cell growth. Patients with bowel or womb cancer should have their tumours assessed for markers of Lynch syndrome, according to guidance for the NHS. If these markers are identified, patients should be referred for genetic testing so the diagnosis can be confirmed and they can get support and advice about cancer risk for themselves and their family. A new study by academics at the University of Edinburgh found not all womb cancer patients are being sent for genetic testing. Researchers examined data on 2,500 womb cancer patients across the UK and Ireland between 2022 and 2023. We have launched a Guide to #LynchSyndrome to help provide information and support to anyone who thinks they may have it, that it may run in the family, or have found out they have — The Eve Appeal (@eveappeal) February 13, 2023 They found that 91% of tumours were tested for markers of Lynch syndrome, but the test results were not routinely communicated to the wider clinical team. This means that follow-up genetic counselling and blood tests were not always arranged. Of the 181 participants eligible for genetic counselling, just under two-thirds (64%) were referred for appointments, according to the study, which has been published in the journal BMJ Oncology. Researchers said those who were referred faced long waits, resulting in high dropout rates, meaning only 48% of those eligible went on to get the test. Today's #LynchSyndromeAwarenessDay. Our policy team sat down with our supporter, Jane, to share her experience. As well as highlighting what else needs to be done to improve Lynch syndrome care. Read our blog: — Bowel Cancer UK (@bowelcanceruk) March 22, 2025 Experts from the university said gaps in testing mean some womb cancer patients with Lynch syndrome go undetected. Family members are also left vulnerable to cancer risk, unaware they may have the condition. Dr Neil Ryan, from the University of Edinburgh, who leads the UK audit and research collaborative in obstetrics and gynaecology, said: 'Despite clear guidance and excellent rates of tumour testing, too many women with Lynch syndrome are still being missed because they're not referred for definitive blood testing in a timely way. 'This not only denies them the chance to reduce their future cancer risk but also prevents their relatives from being tested and protected. 'Tumour testing is only cost-effective if it leads to diagnosis — we urgently need to make mainstream testing truly mainstream.'
